| Authors: |
Schaefer DA; Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Longley RM; Icahn School of Medicine at Mount Sinai, New York, New York., Wolfe ED; Department of Health Systems and Population Health, University of Washington School of Public Health, Seattle, Washington State., Keane EP; Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts., Larizza IS; Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts., Boardman AC; Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts., Rosenberg J; Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts., Mate-Kole M; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Waldman LP; Harvard Medical School, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Majhail N; Sarah Cannon Transplant and Cellular Therapy Network, Nashville, Tennessee., Lee SJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington State., Khera N; Department of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona., Amonoo HL; Harvard Medical School, Boston, Massachusetts; Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts; Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: hermioni_amonoo@dfci.harvard.edu. |
